Molecular Therapy for Hepatocellular Carcinoma
Author Information
Author(s): Greten T F, Korangy F, Manns M P, Malek N P
Primary Institution: Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
Hypothesis
Can targeted therapies improve treatment outcomes for hepatocellular carcinoma (HCC)?
Conclusion
Recent advances in targeted therapies have shown promising results for treating hepatocellular carcinoma.
Supporting Evidence
- Sorafenib is the first drug to show overall survival benefit in advanced HCC.
- Median overall survival increased from 7.9 months in the placebo group to 10.7 months in the sorafenib group.
- High microvessel density predicts poor disease-free survival after resection in HCC patients.
Takeaway
Doctors are finding new medicines that can help people with liver cancer feel better and live longer.
Methodology
This review summarizes data from various clinical trials on targeted therapies for HCC.
Limitations
The review does not provide specific data on all therapies or their long-term effects.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% confidence interval, 0.55–0.87
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website